Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-011399
Filing Date
2025-05-19
Accepted
2025-05-19 09:22:56
Documents
64
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 881368
2 EX-31.1 ex31-1.htm EX-31.1 17527
3 EX-31.2 ex31-2.htm EX-31.2 17305
4 EX-32.1 ex32-1.htm EX-32.1 13563
  Complete submission text file 0001641172-25-011399.txt   5671071

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE awhl-20250331.xsd EX-101.SCH 50729
6 XBRL CALCULATION FILE awhl-20250331_cal.xml EX-101.CAL 53838
7 XBRL DEFINITION FILE awhl-20250331_def.xml EX-101.DEF 242765
8 XBRL LABEL FILE awhl-20250331_lab.xml EX-101.LAB 401032
9 XBRL PRESENTATION FILE awhl-20250331_pre.xml EX-101.PRE 311678
66 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 768216
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Filer) CIK: 0000926617 (see all company filings)

EIN.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34810 | Film No.: 25961831
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)